European Medicines Agency grants Orphan Drug designation for aspartylglucosaminuria (AGU) gene therapy

The investigational treatment is an adeno-associated virus vector with engineered transgene encoding the human AGA gene for patients diagnosed with AGU, an inherited rare, progressively debilitating neurodegenerative lysosomal storage disorder, with no approved treatments.

Source:

Biospace Inc.